Insights

Podcast

Community Oncology Practice Economics - Podcast Part 2 of 3

In part 2 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore the operational realities of oncology practice economics.

Podcast

Community Oncology Practice Economics - Podcast Part 1 of 3

In part 1 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore the current state of oncology practice economics.

Article

Navigating the 340B Maze Amid the Inflation Reduction Act

As the Inflation Reduction Act (IRA) introduces new Maximum Fair Pricing (MFP) rules, integrated delivery networks (IDNs) and manufacturers will face the complexities of navigating overlapping 340B discounts and MFPs.

Revolutionizing Cancer Care: EOM's Second Wind and its Current Impact on Community Oncology Practices

The second Enhancing Oncology Model (EOM) application cycle closed on September 16, signaling shifts in community oncology. Explore our 2024 Community Oncology Report to understand EOM’s current impact and changes from this round.

Article

Bispecific Therapies in Community Oncology: Bridging Insights from CPC+CBEx and Beyond

Explore key takeaways from CPC+CBEx on bispecific therapies, highlighting collaboration between hospitals and community practices to expand access and tackle financial challenges.

Article

Community Oncology: Awareness v Action in the Face of the IRA

The Inflation Reduction Act (IRA) will significantly impact community oncology practice financials. As we approach this shift, our latest research from the 2024 Community Oncology Report reveals a current gap between awareness and action.

Prior Authorization Requirements Continue to Impact Providers

Welcome to the August 2024 edition of our Monthly Insight Series! This month we are combining insights from 3 of our customer segment reports and reflecting on provider and payer relationships.

Article

Notes From ATOPP: Providing Bispecific Antibody Treatments in Community Oncology

The ATOPP Summit covered a range of cutting-edge topics, including the shift toward administering cellular therapies to patients in community oncology settings.

Article

Vertical Payers: “Highly Integrated” by 2026

Welcome to our Monthly Insight Series July 2024 edition! This month we discuss our 2024 research regarding the ever-rising integration across vertical payers’ health plans, PBMs, and SPs, including around manufacturer contracting.

Article

Oncology Clinics Frustrated With Manufacturer Engagement Tactics

Welcome to the June 2024 edition of our Monthly Insight Series! This month we’re discussing oncology clinic concerns with existing manufacturer engagement approaches, using data drawn from our 2024 Community Oncology report, coming later in June.

Article

When Do Payer Pathways Matter?

While provider-initiated oncology clinical pathways are regaining momentum, payer pathways struggle to find a foothold in this space. Still, they can exert impact under certain conditions.

Article

IDNs’ Numerous Strategies and Tools to Manage High-Cost Drugs

Welcome to the May 2024 edition of our Monthly Insight Series. This month we’re exploring the new tools IDNs have deployed to monitor high-cost drugs. This is a preview of findings from our 2024 IDN Oncology Trend Survey, coming at the end of May.

Article

Following the Money: Rx Revenues Underpin Community Oncology Business Models

Welcome to the April 2024 edition of our Monthly Insight Series. This month we’re looking at community oncology practices’ reliance on buy-and-bill drug revenues.

Article

IDN Financial Incentives: Impact on Treatment Prices?

Navigating IDNs requires understanding their financial drivers, revenue streams, and cost management. Here, we look at IDNs' key financial aspects, such as revenue optimization strategies, and examine the potential effects of site-neutral payment reforms.

Article

Provider Economics Drive Oncologist Consolidation

Welcome to the March 2024 edition of our Monthly Insight Series. This month we examine the trend of oncologists consolidating into IDNs and network aggregators.

Article

An Update on What You Need to Know About Pathways

Welcome to the February 2024 edition of our Monthly Insight Series, featuring key findings from our recent column in the Journal of Clinical Pathways. The column was the first in a series on oncologists' awareness and use of pathways.

Article

Oncology Insights: Clinical Decision Support

Welcome to the January 2024 edition of our Monthly Insight Series. This month we are discussing clinical decision support systems in oncology.

Article

Oncology Insights: Notable Quotes from Key Decision Makers

Welcome to the December 2023 edition of our Monthly Insight Series. This month we are discussing standout quotes from discussions we had this year, and how they impact our key customer segments.

Article

What's Going On with Oncology Pathways? Here's What You Need to Know

Welcome to the November 2023 edition of our Monthly Insight Series. This month we are highlighting a few key findings from our recently published report on Oncology Clinical Pathways.

Article

Payer Insight: It’s NOT All About Drugs

Welcome to the October 2023 edition of our Monthly Insight Series. This month we highlight a specific finding from our 2023 Payer Annual Oncology Trend Report that was just released in September: Payers’ top cancer cost targets.

Article

Summer 2023 Recap: Here’s What You Missed From MAI

Welcome to the September 2023 edition of our Monthly Insight Series. This month we are giving a quick overview of the various reports we’ve released to our clients this summer—it’s been a busy one!

Article

Oncology Network Aggregators: Gaining Popularity?

Welcome to the August 2023 edition of our Monthly Insight Series. This month we take a deeper look into independent community oncology practices’ evolving interest in joining oncology network aggregators.

Article

The Enhancing Oncology Model: What Lies Ahead for Participants?

CMMI has launched its new oncology pilot, the Enhancing Oncology Model, sparking questions about its new features vs the Oncology Care Model, the benefits and concerns for participating practices, and CMMI’s ability to successfully implement the program.

Article

IDN Pharmacy Performance Metrics: Opportunities for Manufacturers to Engage

Welcome to the July 2023 edition of our Monthly Insights Series. This month we want to share some more thoughts on opportunities for manufacturer engagement with IDN stakeholders—the IDN pharmacy/pharmacists, in particular.

Article

Clinical Pathways Impact on Treatment Selection

As more providers explore clinical pathways as a tool for increasing clinical consistency and quality, we need to examine adoption benefits and challenges, provider compliance, and potential access risks for manufacturers.

Article

CONFLICTED: Payer Pathways vs Their Own Coverage Policies

Welcome to the May 2023 edition of our Monthly Insight Series. This month we are examining how Payers’ oncology pathways sometimes conflict with their own coverage policies, and how they can differ but still be aligned from a Payer perspective.

Article

Medicare Advantage Growth Will Bring Changes for Cancer Drug Manufacturers

Changes to Medicare, including Medicare Advantage, have important repercussions on patient access to care, oncologists’ treatment decisions, and drug manufacturers’ processes.

Article

Pharmacists’ Shifting Meeting Preferences

Welcome to the April 2023 edition of our Monthly Insight Series. This month we are evaluating the desire among oncology pharmacists to return to in-person meetings.

Article

Humana Quits Commercial

Welcome to the March 2023 edition of our Monthly Insight Series. This month we discuss how Humana terminated its employer group line of business and the implications.

Article

HMP Global Market Access Insights’ 2023 Research Year

We want to give you a look at some of the topics we’re planning to explore this year, as we enter yet another period of rapid change, upheaval, and uncertainty in 2023-2025.